Pathologic proliferation of the plasma cell population can produce a wide spectrum of disorders, ranging from benign solitary plasmacytoma to malignant multiple myeloma. The presentation of the resulting disease can be either localized or systemic, depending on the affected area. Multiple myeloma typically presents with systemic symptoms secondary to skeletal lytic lesions, anemia, renal failure, infection, and hyperviscosity syndrome; a diagnosis of multiple myeloma is not suspected in the absence of these features. Multiple myeloma of the skull base is very rare. We present the case of a 66-year-old man who came to us with a 2-year history of disequilibrium and who was found to have multiple myeloma with extensive involvement of the skull base.
Introduction
Plasma cells represent 0.5 to 1% of all peripheral blood mononuclear cells in normal individuals. 1 The origin of malignant plasma cells is unknown. Multiple myeloma is a neoplastic proliferation of plasma cells with diffuse bone marrow infi ltration and focal osteolytic lesions. Its prevalence is 5 in 100,000 population, and its peak age at presentation is 70 years, which makes it the most common primary malignancy of the skeleton and bone marrow. 2 Common symptoms of this disease are (1) bone pain and tenderness, particularly in the axial skeleton; (2) lassitude secondary to anemia, renal failure, or dehydration; and (3) pyogenic infection. Other signs and symptoms include amyloidosis, neuropathy, signs of hyperviscosity, and bleeding. Investigations for multiple myeloma include a full blood count, measurements of electrolyte and calcium levels, serum and urine electrophoresis, a bone marrow study, and a skeletal survey. The most common modes of treatment are localized radiotherapy and chemotherapy with a multidrug regimen.
Although they are very rare, cases have been reported in which multiple myeloma has progressed to involve the skull base. 3, 4 Also, some isolated cases of solitary plasmacytoma of the skull base have been documented. 5, 6 However, no case has been reported in which the only manifestation of a disseminated multiple myeloma was otologic symptoms secondary to skull base involvement. In this article, we report a case of multiple myeloma of the skull base in which the presenting symptoms were vertigo and ear discomfort.
Case report
A 66-year-old man was referred to the Neurotology and Skull Base Surgery Unit at Addenbrooke's Hospital in Cambridge with a transient and intermittent history of disequilibrium of 2 years' duration. The fi rst episode had lasted 3 days. He experienced another episode 8 months later, at which time he had been diagnosed with labyrinthitis and treated with vestibular sedatives. Another 6 months down the line, he noticed a right-sided ear discomfort and hearing loss along with vertigo. During the subsequent months, the ear discomfort had rapidly progressed to severe pain associated with additional symptoms, which included diplopia, localized headaches in the right occipital area, and some facial numbness in the area of the trigeminal nerve, lip, and tongue.
Otoscopy and a nose and throat examination failed to identify any abnormality. No nystagmus or evidence of current diplopia was found. All cranial nerves were intact, and the results of clinical vestibular testing were normal. No evidence of ataxia or dysdiadochokinesia was seen. Pure-tone audiometry refl ected a mixed hearing loss in the right ear with a 20-dB conductive component in the low frequencies and a ski-slope high-frequency sensorineural hearing loss. The patient's maximum speech discrimination score on the right was 92% at 70 dB with rollover.
Keeping in mind the rapid progression of symptoms, we arranged for further urgent investigations. Computed tomography (CT) of the temporal bones detected the presence of a large destructive mass that was centered on the right petrous apex (fi gure, A). CT also revealed destruction of the right occipital condyle, the right side of the clivus, the body of the sphenoid, the cavernous sinus, and the petrous apex. A small amount of soft tissue was seen extending into the posterior fossa, where it mildly indented the brainstem; the cochlea and semicircular canals were spared. No calcifi cation within the mass was evident. Magnetic resonance imaging (MRI) confi rmed the site and extent of the mass (fi gure, B, C, and D). The mass was slightly hyperintense to brain on T1-and T2-weighted sequences. The lesion showed almost homogeneous enhancement. Bilateral carotid arteriography showed a marked vascular supply to the lesion from the external carotid injection. The differential diagnoses considered at this stage were chordoma, lymphoma, glomus tumor, chondrosarcoma, plasmacytoma, and myeloma.
In view of these possible diagnoses, the patient was admitted for hematologic evaluation. He was mildly anemic, his serum lambda free-light-chain level was markedly elevated, and he was positive for Bence Jones protein. A bone marrow aspiration revealed that plasma cells with a neoplastic phenotype were predominant with reduced hematopoiesis. A skeletal survey showed multiple lytic lesions within the skull, in the right humerus, in multiple ribs, and in both proximal femurs. Wedge compression fractures of the T6 and T7 vertebrae were also noted. Based on our clinical evaluation and the results of all the investigations, we reached a diagnosis of multiple myeloma.
The patient was treated with a course of radiotherapy followed by chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone. He was then transferred back to the hematology unit of the referring hospital. Some of his symptoms (i.e., hearing loss, diplopia, and poor appetite) began to abate, and he continued on regular follow-up.
Discussion
Plasma cells are mature blood cells derived from B lymphocytes. The function of these cells is to provide specifi c noncellular immunity by producing antibodies against antigens. Plasmablasts found in primary and secondary follicles of lymph nodes, the spleen, and Peyer patches are believed to be the progenitors of marrow plasma cells. 1 Neoplastic transformation of plasma cells is regarded as a multistep process. The reason for this has been postulated to be an early initiating mutation during the pre-plasma-cell phase. This theory is supported by the fact that there is a high frequency of expression of myeloid, monocytic, erythroid, or megakaryocytic
Figure. The right-sided skull base lesion is seen on axial CT with bone window (A); axial T1-weighted, gadolinium-enhanced MRI (B); axial T2-weighted MRI (C); and coronal T1-weighted gadolinium-enhanced MRI (D).
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surface antigens. 7 This indicates that the initial insult occurs in progenitors common to both the myeloid and lymphoid lineages. It is rare for plasma cells to be found in high numbers in the peripheral blood until multiple myeloma enters a terminal phase. Multiple myeloma is a classic example of a monoclonal neoplasm. The homogeneity of M protein refl ects the clonality of the cells, indicating that these multiplying cells have descended from a single precursor. 8 The growth pattern in multiple myeloma is described mathematically by a Gompertzian model-that is, the tumor growth fraction decreases exponentially with time. 1 The clinical presentation of this condition is dictated by four components: malignant plasma cell proliferation, M protein production, renal failure, and immunodefi ciency. Multiplication of the plasma cells occurs principally in the red bone marrow in both diffuse and nodular patterns, resulting in progressive replacement of hematopoietic tissue. This leads to anemia, neutropenia, and thrombocytopenia. 9 Even at the earliest stage of presentation, malignant cells are widely disseminated to the axial skeleton in 95% of caseshence its common clinical features. 9 However, this was not the case with our patient. Lytic bone lesions along with hypercalcemia results in (1) wedging or collapse of vertebrae, (2) pathologic fractures, and (3) diffuse or localized bone pain. These in fact are the predominant presenting features in 60% of patients. 9 Other features include fatigue, pyogenic infection, amyloidosis, neuropathy, signs of hyperviscosity, and bleeding.
The diagnostic criteria for multiple myeloma are classifi ed as major and minor. The major criteria are (1) plasmacytoma on biopsy, (2) a plasma cell level of more than 30% on bone marrow biopsy, (3) a monoclonal band on electrophoresis greater than 35g/L for IgG or 20g/L for IgA, and (4) more than 1 g of light chains ex-creted in the urine per day. The minor criteria are (1) a plasma cell level of 10 to 30% on bone marrow biopsy, (2) an abnormal monoclonal band, but with levels less than those listed among the major criteria, (3) lytic bone lesions, and (4) immunosuppression. Based on formal investigations, the diagnosis of multiple myeloma requires that either one major and one minor criterion be met or that three minor criteria be met, including the fi rst two listed. 1 Involvement of the skull base in multiple myeloma is very rare. In a large case study, Silverstein and Doniger reported that only 3% of multiple myelomas presented as cranial or intracranial tumors; such involvement is often seen in the advanced stage of the disease. 10 The features of skull base multiple myeloma include otalgia, headache, a postauricular mass, multiple cranial nerve palsies, and vertigo. The most common cranial nerves affected are II, III, IV, and VI. In some studies, isolated IIIrd and VIth nerve palsies in different cases have been noted. 11 CT and MRI have greatly increased the sensitivity of detecting the bone disease in multiple myeloma. 2 MRI has been found to be superior to CT for screening large portions of the vertebral column and spinal canal and also to visualize soft-tissue abnormalities (table). 2, 12 The standard clinical staging system for multiple myeloma is the Durie and Salmon system, which is largely based on myeloma cell mass; lesions are classifi ed as stage I, II, or III. 13 The prognosis of myelomatosis is highly associated with the Durie and Salmon stage. Other prognostic indicators include serum beta 2 -microglobulin and albumin levels and the degree of renal failure. It is important to consider both cytoreduction and ancillary treatment to manage complications of this disease.
The treatment of choice is palliative local radiotherapy and systemic multidrug chemotherapy. 8, 14 Classically, melphalan and prednisolone have been used as the 15 In conclusion, skull base involvement in multiple myeloma is rare, and the clinical features of this entity can be vague. Still, skull base lesions, including multiple myeloma, should be considered in the differential diagnosis of patients with nonspecifi c neurotologic symptoms. A thorough hematologic and radiologic investigation is required in order to accurately diagnose this possibility so that early and appropriate treatment can be instituted.
